All In Biotech

Free tool

FAERS Monitor: Vytorin

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021687 or its brand name (Vytorin, Ezetimibe, Simvastatin). Reports on generic versions are filed under their own applications.

Reports

15,138

Serious

9,500

63% of reports

Hospitalization

4,785

Death reported

857

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea1,013
  • drug ineffective821
  • fatigue777
  • dizziness734
  • pain708
  • myalgia675
  • dyspnoea647
  • diarrhoea605
  • asthenia604
  • headache566
  • pain in extremity550
  • arthralgia533
  • myocardial infarction518
  • weight decreased504
  • fall476

Reports by year received

View as table
YearReports
200440
2005627
2006949
20071,301
20081,554
20091,189
20101,679
20111,130
2012987
2013801
2014830
2015912
2016751
2017563
2018447
2019407
2020250
2021197
2022132
202397
202498
2025110
202687

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,039,021 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
myalgiaSignal6755.55.12,513
myocardial infarctionSignal5184.13.81,234
pain in extremitySignal5502.62.4545
weight decreasedSignal5042.52.3462
astheniaSignal6042.22.1417
dizzinessSignal7342.01.9401
fall4762.01.8236
arthralgia5331.81.6186
nausea1,0131.81.7358
pain7081.61.5164
dyspnoea6471.61.5144
fatigue7771.41.387
diarrhoea6051.31.244
headache5661.31.230
drug ineffective8210.90.818

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.